Summary
Gilead Sciences, Inc. reported robust revenue growth in 2002, driven primarily by strong sales of Viread, its HIV treatment, which nearly doubled its revenue contribution compared to 2001. AmBisome, an antifungal, also showed solid growth, contributing significantly to the company's overall performance. The company's acquisition of Triangle Pharmaceuticals in January 2003 marked a strategic move to bolster its antiviral pipeline, particularly for HIV and Hepatitis B, with the inclusion of emtricitabine and other promising drug candidates. Financially, Gilead achieved operating profitability in 2002 after years of losses, indicating a positive trajectory. However, the company faces ongoing challenges, including increasing competition in key therapeutic areas and the complexities of integrating new acquisitions. Gilead also highlighted its commitment to global health initiatives, announcing plans to supply Viread at cost to developing countries, demonstrating a balance between commercial objectives and social responsibility.
Key Highlights
- 1Total revenues increased significantly to $466.8 million in 2002, up from $233.8 million in 2001, largely driven by Viread sales.
- 2Viread product sales reached $225.8 million in 2002, accounting for 48% of total revenues, a substantial increase from $15.6 million in 2001.
- 3AmBisome sales grew 13% to $185.7 million in 2002, representing 40% of total product sales.
- 4Gilead achieved operating income of $81.0 million in 2002, marking a shift to profitability from an operating loss in 2001.
- 5The acquisition of Triangle Pharmaceuticals for $525.0 million was completed in January 2003, strengthening Gilead's antiviral portfolio, particularly for HIV and Hepatitis B.
- 6Research and Development expenses decreased to $134.8 million in 2002 from $185.6 million in 2001, partly due to the divestiture of the oncology assets.
- 7Gilead's common stock is traded on The Nasdaq Stock Market under the symbol 'GILD'.